On February 16, 2026 Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment of solid tumours, reported that it will present interim clinical data at the 2026 European Association of Urology (EAU) Annual Congress, taking place in London, UK, 13th – 16th March, and the 2026 American Urological Association (AUA) Annual Meeting, taking place in Washington, DC, US, 15th – 18th May. Both conferences have accepted Prokarium’s work for oral presentation, which reflects the growing recognition of the high potential of its bacterial immunotherapy platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At EAU and AUA, Prokarium will share important emerging findings from the company’s ongoing Phase 1/1b clinical trial, PARADIGM-1 (NCT06181266), assessing the safety, pharmacology, and preliminary clinical efficacy of ZH9 treatment in patients with non-muscle invasive bladder cancer (NMIBC).
"We are delighted that our work has been selected for oral presentations at two of the most prestigious global urology meetings, in particular a podium presentation at the AUA" said Ibs Mahmood, CEO. "These invitations underscore the growing interest in our transformational treatment aiming to shift the standard of care for patients with bladder cancer, and I think the community is going to be very excited when they hear the results"
The 41st European Association of Urology Annual Congress Information:
Presentation Title: PARADIGM 1 – A multi-center Phase 1 study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first interim review (Abstract ID: A0089)
Session Title: High-risk NMIBC: Evolving BCG–immunotherapy strategies and technical advances in TURB (Abstract Session 05)
Session Date and Time: Friday 13th March, 16:20 – 16:56
The American Urology Association Annual Meeting information:
Presentation title: PARADIGM 1 – A multi-center Phase 1 study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first interim review (Abstract ID: 26-1116)
Session Title: Podium Presentation PD09, Bladder Cancer: Non-Invasive III
Session Date and Time: Saturday 16th May, 07:00 – 09:00
(Press release, Prokarium, FEB 16, 2026, View Source [SID1234662689])